Regional Control of Head and Neck Melanoma With Selective Neck Dissection | Dermatology | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.212.130. Please contact the publisher to request reinstatement.
1.
Maguire-Eisen  M.  Skin cancer: a growing health problem for children.  Semin Oncol Nurs. 2013;29(3):206-213.PubMedGoogle ScholarCrossref
2.
Leong  SP.  Role of selective sentinel lymph node dissection in head and neck melanoma.  J Surg Oncol. 2011;104(4):361-368.PubMedGoogle ScholarCrossref
3.
Balch  CM, Soong  SJ, Gershenwald  JE,  et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the AJCC melanoma staging system.  J Clin Oncol. 2001;19(16):3622-3634.PubMedGoogle Scholar
4.
Urist  MM, Balch  CM, Soong  S, Shaw  HM, Milton  GW, Maddox  WA.  The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma.  Cancer. 1985;55(6):1398-1402.PubMedGoogle ScholarCrossref
5.
Drepper  H, Köhler  CO, Bastian  B,  et al.  Benefit of elective lymph node dissection in subgroups of melanoma patients.  Cancer. 1993;72(3):741-749.PubMedGoogle ScholarCrossref
6.
Veronesi  U, Adamus  J, Bandiera  DC,  et al.  Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities.  Cancer. 1982;49(11):2420-2430.PubMedGoogle ScholarCrossref
7.
Sim  FH, Taylor  WF, Ivins  JC, Pritchard  DJ, Soule  EH.  A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: preliminary results.  Cancer. 1978;41(3):948-956.PubMedGoogle ScholarCrossref
8.
Balch  CM, Soong  SJ, Bartolucci  AA,  et al.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger.  Ann Surg. 1996;224(3):255-266.PubMedGoogle ScholarCrossref
9.
O’Brien  CJ, Petersen-Schaefer  K, Ruark  D, Coates  AS, Menzie  SJ, Harrison  RI.  Radical, modified, and selective neck dissection for cutaneous malignant melanoma.  Head Neck. 1995;17(3):232-241.PubMedGoogle ScholarCrossref
10.
Fisher  SR.  Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998.  Laryngoscope. 2002;112(1):99-110.PubMedGoogle ScholarCrossref
11.
Mack  LA, McKinnon  JG.  Controversies in the management of metastatic melanoma to regional lymphatic basins.  J Surg Oncol. 2004;86(4):189-199.PubMedGoogle ScholarCrossref
12.
Turkula  LD, Woods  JE.  Limited or selective nodal dissection for malignant melanoma of the head and neck.  Am J Surg. 1984;148(4):446-448.PubMedGoogle ScholarCrossref
13.
Van de Vrie  W, Eggermont  AM, Van Putten  WL, Wiggers  T.  Therapeutic lymphadenectomy in melanomas of the head and neck.  Head Neck. 1993;15(5):377-381.PubMedGoogle ScholarCrossref
14.
Jonk  A, Strobbe  LJ, Kroon  BB,  et al.  Cervical lymph-node metastasis from cutaneous melanoma of the head and neck: a search for prognostic factors.  Eur J Surg Oncol. 1998;24(4):298-302.PubMedGoogle ScholarCrossref
15.
Coit  DG, Thompson  JA, Andtbacka  R,  et al. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology, melanoma. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Accessed January 24, 2014.
16.
Morton  DL, Thompson  JF, Cochran  AJ,  et al; MSLT Group.  Sentinel-node biopsy or nodal observation in melanoma.  N Engl J Med. 2006;355(13):1307-1317.PubMedGoogle ScholarCrossref
17.
Erman  AB, Collar  RM, Griffith  KA,  et al.  Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma.  Cancer. 2012;118(4):1040-1047.PubMedGoogle ScholarCrossref
18.
Xing  Y, Badgwell  BD, Ross  MI,  et al.  Lymph node ratio predicts disease-specific survival in melanoma patients.  Cancer. 2009;115(11):2505-2513.PubMedGoogle ScholarCrossref
19.
Davar  D, Tarhini  AA, Kirkwood  JM.  Adjuvant therapy for melanoma.  Cancer J. 2012;18(2):192-202.PubMedGoogle ScholarCrossref
Original Investigation
November 2014

Regional Control of Head and Neck Melanoma With Selective Neck Dissection

Author Affiliations
  • 1Department of Otolaryngology–Head and Neck Surgery, Oregon Health and Science University, Portland
  • 2Division of Surgical Oncology, Department of Surgery, Oregon Health and Science University, Portland
JAMA Otolaryngol Head Neck Surg. 2014;140(11):1014-1018. doi:10.1001/jamaoto.2014.2056
Abstract

Importance  Historically, patients with cervical metastases from melanoma of the head and neck were treated with a radical neck dissection. This study evaluates the efficacy of limiting the extent of lymphadenectomy in this high-risk population.

Objectives  To determine whether limiting the extent of lymphadenectomy for patients with biopsy-proven melanoma has a negative effect on regional control. Our hypothesis was that performing a more limited lymphadenectomy does not have a negative impact on regional control.

Design, Setting, and Participants  A retrospective, single-cohort study was performed using a prospectively collected database of patients with head and neck melanoma with histopathologically positive lymph nodes after modified radical (MRND) or selective neck dissection (SNDs) performed at a high-volume, academic, tertiary care center.

Interventions  Lymphadenectomy was performed as clinically indicated.

Main Outcomes and Measures  Primary end points were regional recurrence and regional recurrence free survival. Univariable and multivariable analyses were conducted using multiple patient characteristics.

Results  Forty-one patients underwent SND or MRND from 2001 through 2010. The median number of positive nodes was 1 (range, 1-16). Twenty-six patients (63%) received adjuvant radiation and 23 patients (56%) received adjuvant immunotherapy or chemotherapy. The median follow-up time was 17 months (range, 1-116 months). Regional control was achieved in 29 patients (71%). Median regional recurrence-free survival was 21 months (range, 1-116 months). Age (hazard ratio [HR], 1.13; 95% CI, 1.01-1.26), total number of nodes examined (HR, 1.05; 95% CI, 1.01-1.10), and number of sentinel lymph nodes examined (HR, 1.45; 95% CI, 1.01-2.09) were all significantly associated with increased recurrence-free survival. Tumor depth, extracapsular spread, number of nodes positive, prior SLNB, extent of lymphadenectomy, and adjuvant therapy were not significant.

Conclusions and Relevance  Limiting the extent of lymphadenectomy with frequent use of adjuvant radiation therapy is effective in achieving regional control of head and neck melanoma with cervical metastases.

×